Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study

Wroblewski John J.; Hu Allen Y.

首页> 外文期刊>Ophthalmic surgery, lasers & imaging retina >Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study

【24h】

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study

机译：外用角鲨胺0.2％和玻璃体内雷珠单抗0.5 mg作为因分支和中央视网膜静脉阻塞而引起的黄斑水肿的联合治疗：一项开放标签，随机研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND AND OBJECTIVE: To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, New York, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) on macular edema (ME) secondary to retinal vein occlusion (RVO).

机译：背景与目的：评估角鲨胺（OHR-102;纽约州纽约奥尔制药公司）和兰尼单抗（Lucentis;加利福尼亚州南旧金山的基因泰克公司）对继发于视网膜静脉阻塞（RVO）的黄斑水肿（ME）的影响。

著录项

来源
《Ophthalmic surgery, lasers & imaging retina》 |2016年第10期|共10页
作者
Wroblewski John J.; Hu Allen Y.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study [J] . Wroblewski John J., Hu Allen Y. Ophthalmic surgery, lasers & imaging retina . 2016,第10期

机译：外用角鲨胺0.2％和玻璃体内雷珠单抗0.5 mg作为因分支和中央视网膜静脉阻塞而引起的黄斑水肿的联合治疗：一项开放标签，随机研究
2. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION 6-MONTH RESULT [J] . Terashima Hiroko, Hasebe Hiruma, Okamoto Fumiki, Retina . 2019,第7期

机译：玻璃体内ranibizumab的组合治疗和亚阈值微型光凝用于黄斑水肿中的分支视网膜静脉闭塞6个月的结果
3. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion A Randomized Clinical Trial [J] . Hykin Philip, Prevost A. Toby, Vasconcelos Joana C., JAMA ophthalmology . 2019,第11期

机译：宫颈疗法与Ranibizumab的临床疗效与AfliBelcept对中央视网膜静脉闭塞的黄斑水肿vs Aflibercept Vs Aflibercept vs Aflibelcepab。随机临床试验
4. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION [O] . Hiroko Terashima, Hiruma Hasebe, Fumiki Okamoto, -1

机译：视网膜内静脉阻塞继发性黄斑水肿的玻璃体内腔注射与亚阈值微光凝术联合治疗
5. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION [O] . Hiroko Terashima, Hiruma Hasebe, Fumiki Okamoto, 2019

机译：玻璃体内Ranibizumab的组合治疗和亚阈值微型光凝用于黄斑水肿次级的分支视网膜静脉闭塞

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study

摘要

著录项

相似文献

相关主题

期刊订阅